Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk
Open Access
- 18 November 2010
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 12 (6) , 1-8
Abstract
Introduction: Breast cancer is frequently a hormonally dependent cancer, and associations of circulating estrogens and androgens with subsequent breast cancer risk are well established in postmenopausal women. Associations of serum estrogens and androgens with breast cancer risk in premenopausal women are less well studied. The objective of this study was to determine whether estradiol and testosterone levels in serum collected before menopause are associated with subsequent breast cancer risk. Methods: We conducted a prospective case-control study of 266 participants who were registered in the Columbia, Missouri, Serum Bank and not using exogenous hormones at the time of blood collection. Each of 98 insitu or invasive breast cancer cases with prediagnostic serum collected before menopause was matched to two controls by age, date, menstrual cycle day, and time of day of blood collection. Estradiol and testosterone concentrations were quantified by using specific radioimmunoassays, and sex hormone-binding globulin (SHBG) was quantified with a chemiluminescent immunoassay to allow calculation of the non-SHBG bound hormone fractions. Data were analyzed by using conditional logistic regression. All tests of statistical significance were two-sided. Results: Serum testosterone was strongly and significantly associated with breast cancer risk. The relative odds (OR) for increasing quartiles of total testosterone were 1.0, 2.1 (95% confidence interval (CI) 0.9 to 4.8), 1.5 (95% CI, 0.6 to 3.4), and 3.3 (95% CI, 1.5 to 7.5, Ptrend = 0.006). Comparable ORs for the non-SHBG bound fraction of testosterone that is bioavailable were 1.0, 1.7 (95% CI, 0.7 to 4.2), 1.7 (95% CI, 0.7 to 4.0), and 4.2 (95% CI, 1.6 to 10.9, Ptrend = 0.002). Total and non-SHBG-bound estradiol were not associated with breast cancer, but extreme variation in levels across the menstrual cycle coupled with relatively small numbers, particularly for analyses stratified by cycle phase, limited the power to detect associations. Conclusions: Results suggest that premenopausal women with elevated serum testosterone levels are at an increased risk of breast cancer.Keywords
This publication has 37 references indexed in Scilit:
- Intratumoral Estrogen Disposition in Breast CancerClinical Cancer Research, 2010
- Testosterone and Biological Characteristics of Breast Cancers in Postmenopausal WomenCancer Epidemiology, Biomarkers & Prevention, 2009
- Prospective Case-Control Study of Serum Mullerian Inhibiting Substance and Breast Cancer RiskJNCI: Journal of the National Cancer Institute, 2009
- Regulation of breast cancer-associated aromatase promotersCancer Letters, 2009
- Changes over 14 Years in Androgenicity and Body Mass Index in a Biracial Cohort of Reproductive-Age WomenThe Journal of Clinical Endocrinology & Metabolism, 2008
- Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppressionThe Journal of Steroid Biochemistry and Molecular Biology, 2008
- Endogenous Steroid Hormone Concentrations and Risk of Breast Cancer Among Premenopausal WomenJNCI: Journal of the National Cancer Institute, 2006
- Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC)JNCI: Journal of the National Cancer Institute, 2005
- Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- Endogenous sex hormones and subsequent breast cancer in premenopausal womenInternational Journal of Cancer, 2004